Trovagene Using Bio-Rad Digital PCR System for Trans-Renal Pancreatic Cancer MDx | GenomeWeb

This article has been updated from a previous version to correct the list price of the QX100 system.

A Trovagene official this week disclosed that the company is using Bio-Rad's QX100 Droplet Digital PCR system for a non-invasive, urine-based molecular test it is developing to detect and monitor the progression of pancreatic cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.